Author: Matthew

You may know the chemical 4-phosphoryloxy-N,N-dimethyltryptamine by its more common name, psilocybin. Long used as a sacrament among indigenous peoples in the Americas — and more recently branded as an illicit party drug — in recent years, the active ingredient in psychedelic mushrooms has received a lot of attention from scientists for potential to treat substance use disorder, anxiety, and depression.

In their review of seven published psilocybin clinical trials, the team led by Kelan Thomas, assistant professor of clinical sciences at Touro University California, concluded that psilocybin-assisted psychotherapy shows strong potential for improving outcomes in patients living with depression, anxiety, and substance use disorder.

The advantage of psilocybin-assisted therapy, they write, is that it provides significant benefits for patients who haven’t responded to therapy or medication. Patients can also show improvement after just a few six-hour “medicated” therapy sessions and a few weeks of follow-up therapy.

These studies all investigated the use of psilocybin in strictly controlled clinical conditions under the supervision of therapists and other health professionals. Additionally, all of the clinical trials investigated by the researchers consisted of small groups of subjects — as few as nine for an open-label (non-blinded) trial investigating obsessive-compulsive disorder and as many as 51 in a double-blind study of cancer-related depression and anxiety.

As psychological and psychiatric researchers have gained greater access to brain imaging technologies like fMRI, scientists have formed new hypotheses about the physiological roots of psychological disorders.

These new attitudes among scientists run counter to those of the law enforcement community. In most of the United States — New Mexico seems to have found a loophole — psilocybin is still classified as a Schedule I substance. This means it has “a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision,” according to the Drug Enforcement Administration. When — or whether — the DEA will take the most recent scientific data into account, however, remains to be seen.

Inverse

Three different psychedelic drugs that are known to produce altered states of consciousness and that have been used illegally for recreation are the subject of a new study. Psilocybin, a naturally occurring psychedelic compound that is produced by magic mushrooms, Lysergic acid diethylamide (LSD) and ketamine are the subjects of the new study. Researchers set out to determine if magic mushrooms, LSD, and ketamine actually increase “global neural signal diversity.” The researchers wanted to know if the psychedelic state is actually an elevated state of consciousness. The research was published this month in Scientific Reports in Nature.

They say that their research indicates that magic mushrooms and other psychedelic drugs really do push the user into an elevated state of consciousness.

“For all three, we find reliably higher spontaneous signal diversity, even when controlling for spectral changes. This increase is most pronounced for the single-channel LZ complexity measure, and hence for temporal, as opposed to spatial, signal diversity. We also uncover selective correlations between changes in signal diversity and phenomenological reports of the intensity of psychedelic experience. This is the first time that these measures have been applied to the psychedelic state and, crucially, that they have yielded values exceeding those of normal waking consciousness. These findings suggest that the sustained occurrence of psychedelic phenomenology constitutes an elevated level of consciousness – as measured by neural signal diversity.”

The researchers say that their data suggests that the psychedelic state brought on by magic mushrooms and some other drugs lies above other states, including wakeful rest, when compared using a one-dimensional scale that is defined by brain signal diversity.

Magic mushrooms have been gaining greater recognition for the drug’s potentially positive effects. For example, the B.C. Centre on Substance Use, which researches drug abuse in British Columbia, is actually planning clinical trials to see if psychedelic drugs might be able to help people overcome addiction to opioid drugs, CBC reported. A John Hopkins University study from a couple of years ago found that magic mushroom’s active ingredient could help smokers overcome their addiction to cigarettes. Eight out of 10 study participants were still not smoking six months after they quit when using the compound in magic mushrooms and cognitive behavioral therapy.

“Therapeutic outcomes are often correlated with a mystical or a spiritual-type experience. People often have deep insights about themselves and their relationships with others and with God — and sometimes, as a consequence, have significant behavioral changes,” Dr. Kenneth Tupper, of the B.C. Centre on Substance Use, told CBC.

Inquisitr

Hallucinogens are a wide group of drugs with a diverse range of capabilities. Some have been proven to alleviate ailments like PTSD and anxiety; others will definitely make you crap your pants while thinking your roommate has turned into a giant crane. The two most popular hallucinogens are magic mushrooms and LSD, technically known as lysergic acid diethylamide. While they have similar effects, both drugs have enough differences between them that any potential user should be less than chill about considering them the same.

Here’s the science you need to know to understand how LSD and magic mushrooms affect the body in their own, trippy way:

Magic Mushrooms Are Natural, LSD Is Not

While LSD was invented in 1938, mushrooms containing the naturally occurring psychedelic compound psilocybin can be found in regions within South America, Mexico, and the United States. It’s estimated that there are over 200 species of psychedelic mushrooms.

LSD was synthesized by Swiss scientist Albert Hoffman, who later famously took the drug himself and went on a bike ride on April 19, 1934. The clear, odorless, and tasteless drug is made from lysergic acid, which is found on the fungus that typically grows on grains.

Both Drugs Trip Out the Brain, but One Lasts Way Longer

Magic mushrooms and LSD involve chemicals that bond with the brain’s serotonin receptors. When someone takes LSD, their sympathetic nervous system is stimulated, which causes a rise in blood-sugar levels, an increase in body temperature, and pupillary dilation. The body confuses LSD for serotonin and sends it towards the brain’s synaptic cleft. This allows LSD molecules to bind to serotonin receptor proteins.

LSD and Mushrooms May Both Be Future Antidepressants

An increasing swath of scientific evidence demonstrates both substances have the potential to treat addiction, obsessive-compulsive disorder, anxiety, and PTSD. In a small study conducted in 2014, scientists found that it could be magic mushroom’s impact on serotonin receptors that causes heightened emotions and a slight loss of identity — which may be why the substance helps with anxiety. A brain on mushrooms, they note, is much like a brain that is dreaming.

The more researchers examine a tripped out brain, the more they’ll be able to leverage the power of these drugs to help us out in the future.

Inverse